TREATMENT OF IMMUNE DISEASES MEDIATED BY TYPE 2 ASSISTANT CELLS.

摘要

The use of a compound selected from the group consisting of the retinoid antagonists a) RAR-alpha- antagonists of formulas in which R1 is C5-10 alkyl, and R2 and R3 independently of each other are hydrogen or fluorine; b) RAR-alpha beta antagonists of formulas in which R4 is diamantil, X is O or NH, R5 is phenyl or benzyl, and in which optionally ring A or ring B are optionally present; c) RAR-beta, gamma antagonists of the formula wherein R6 and R7 are independently of each other hydroxy, C1-4 alkoxy, optionally branched C1-5 alkyl or adamantyl; d) RAR-gamma antagonists of formulas e) RAR-alpha, beta, gamma antagonists of formulas in which Y is -CH2- or sulfur and Z is -CH = or nitrogen, and R8 is hydrogen or C1-4 alkyl ; f) RXR antagonists of the formula in which the dotted bond is optional; and, when the dotted bond is present, R9 is methyl and R10 is hydrogen; and, when the dotted bond is not present, R9 and R10 together are methylene to form a cis-substituted cyclopropyl ring; R11 is C1-4 alkoxy; and pharmaceutically acceptable salts, and pharmaceutically acceptable hydrolysable esters thereof, as an active ingredient for the preparation of a medicament for the treatment of immune diseases mediated by type 2 helper T cells (Th2), such as allergic diseases mediated by immunoglobulin E (IgE), or for the treatment of immune diseases mediated by Th2-related cytokines, such as IL-4 and IL-5, in which the active ingredient is used in combination with a pharmaceutically acceptable carrier.